CA2693390A1 - Derives de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procedes d'utilisation et procedes de preparation de ceux-ci - Google Patents
Derives de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procedes d'utilisation et procedes de preparation de ceux-ci Download PDFInfo
- Publication number
- CA2693390A1 CA2693390A1 CA2693390A CA2693390A CA2693390A1 CA 2693390 A1 CA2693390 A1 CA 2693390A1 CA 2693390 A CA2693390 A CA 2693390A CA 2693390 A CA2693390 A CA 2693390A CA 2693390 A1 CA2693390 A1 CA 2693390A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- composition
- alkyl
- cancer
- additional embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
- A01N41/04—Sulfonic acids; Derivatives thereof
- A01N41/06—Sulfonic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pest Control & Pesticides (AREA)
- Hospice & Palliative Care (AREA)
- Dentistry (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2924436A CA2924436A1 (fr) | 2007-07-30 | 2008-07-28 | Combinaisons pharmaceutiques de n-3(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide comme inhibiteurs de mek et methodes d'utilisation |
CA2924418A CA2924418A1 (fr) | 2007-07-30 | 2008-07-28 | Derives de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procedes d'utilisation et procedes de preparation de ceux-ci |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/830,733 US8101799B2 (en) | 2005-07-21 | 2007-07-30 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US11/830,733 | 2007-07-30 | ||
US3446408P | 2008-03-06 | 2008-03-06 | |
US3446608P | 2008-03-06 | 2008-03-06 | |
US61/034,466 | 2008-03-06 | ||
US61/034,464 | 2008-03-06 | ||
US4488608P | 2008-04-14 | 2008-04-14 | |
US61/044,886 | 2008-04-14 | ||
PCT/US2008/071392 WO2009018233A1 (fr) | 2007-07-30 | 2008-07-28 | Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2924418A Division CA2924418A1 (fr) | 2007-07-30 | 2008-07-28 | Derives de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procedes d'utilisation et procedes de preparation de ceux-ci |
CA2924436A Division CA2924436A1 (fr) | 2007-07-30 | 2008-07-28 | Combinaisons pharmaceutiques de n-3(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide comme inhibiteurs de mek et methodes d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2693390A1 true CA2693390A1 (fr) | 2009-02-05 |
CA2693390C CA2693390C (fr) | 2017-01-17 |
Family
ID=40304796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2693390A Expired - Fee Related CA2693390C (fr) | 2007-07-30 | 2008-07-28 | Derives de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procedes d'utilisation et procedes de preparation de ceux-ci |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP2184984A4 (fr) |
JP (3) | JP2010535232A (fr) |
KR (3) | KR20150091434A (fr) |
CN (2) | CN103479604B (fr) |
AP (1) | AP2817A (fr) |
AU (2) | AU2008282338B2 (fr) |
BR (1) | BRPI0815659A2 (fr) |
CA (1) | CA2693390C (fr) |
CO (1) | CO6470808A2 (fr) |
CR (1) | CR11244A (fr) |
DO (1) | DOP2010000045A (fr) |
EA (2) | EA020624B1 (fr) |
EC (1) | ECSP109910A (fr) |
HK (1) | HK1147396A1 (fr) |
HN (1) | HN2010000203A (fr) |
IL (1) | IL203296A (fr) |
MA (1) | MA31881B1 (fr) |
MX (1) | MX2010001244A (fr) |
NZ (1) | NZ582929A (fr) |
PH (1) | PH12015501914A1 (fr) |
SV (1) | SV2010003469A (fr) |
TN (1) | TN2010000049A1 (fr) |
WO (1) | WO2009018233A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
EP2291350A4 (fr) * | 2008-04-14 | 2012-09-19 | Ardea Biosciences Inc | Compositions et leurs procédés de préparation et d utilisation |
KR20180001582A (ko) * | 2008-09-09 | 2018-01-04 | 에프. 호프만-라 로슈 아게 | 아실 설폰아미드의 다형체 |
WO2010037041A2 (fr) | 2008-09-26 | 2010-04-01 | Oncomed Pharmaceuticals, Inc. | Agents se liant aux récepteurs frizzled et leurs utilisations |
UY32486A (es) * | 2009-03-11 | 2010-10-29 | Ardea Biosciences Inc | Tratamiento del cáncer de páncreas |
CN103948600A (zh) * | 2009-03-11 | 2014-07-30 | 阿迪生物科学公司 | 用于治疗特定癌症的包含rdea119/bay869766的药物组合 |
WO2011047055A2 (fr) | 2009-10-13 | 2011-04-21 | Allostem Therapeutics Llc | Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies |
WO2011047788A1 (fr) * | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Benzosulfonamides substitués |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
CN102649773A (zh) * | 2011-02-23 | 2012-08-29 | 苏州波锐生物医药科技有限公司 | 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途 |
BR112013027448A2 (pt) * | 2011-04-28 | 2020-09-01 | Sloan-Kettering Institute For Cancer Research | terapia de combinação com hsp90 |
EP2714652B8 (fr) * | 2011-05-27 | 2018-09-05 | Ardea Biosciences, Inc. | Synthèse chirale de n-{3,4-difluoro-2-[(2-fluoro-4-iodophényl)amino]-6-méthoxyphényl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides |
EP2788378A4 (fr) * | 2011-12-09 | 2015-09-09 | Oncomed Pharm Inc | Thérapie d'association pour le traitement du cancer |
WO2013109142A1 (fr) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie |
EP2854779A1 (fr) * | 2012-05-31 | 2015-04-08 | Bayer Pharma Aktiengesellschaft | Biomarqueurs pour la détermination de la réponse efficace de traitements de patients atteints d'un carcinome hépatocellulaire (hcc) |
CA3015208C (fr) | 2012-06-04 | 2024-01-02 | Pharmacyclics Llc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
FI3702351T3 (fi) * | 2012-10-19 | 2024-01-24 | Array Biopharma Inc | MEK-inhibiittorin käsittävä koostumus |
AU2013337702A1 (en) | 2012-11-02 | 2015-05-21 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor |
JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路インヒビターによる処置の方法およびモニタリング |
EP2848246A1 (fr) | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Compositions pharmaceutiques contenant du refametinib |
EP3046557A1 (fr) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Association de rock et de la voie mapk |
WO2015041534A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk en combinaison avec raf/erk/mek |
WO2015156674A2 (fr) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Méthode de traitement du cancer |
WO2015178770A1 (fr) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions pour le traitement du cancer |
WO2016033094A1 (fr) | 2014-08-25 | 2016-03-03 | Aimmune Therapeutics, Inc. | Formulations de protéines d'oeuf et leurs procédés de fabrication |
KR20170122220A (ko) | 2015-03-03 | 2017-11-03 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나제 저해제의 약제학적 제제 |
SG11201911859QA (en) * | 2017-06-16 | 2020-01-30 | Beta Pharma Inc | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
JP2575590B2 (ja) * | 1992-07-31 | 1997-01-29 | 塩野義製薬株式会社 | トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法 |
JP3657002B2 (ja) * | 1992-08-25 | 2005-06-08 | ジー.ディー.サール アンド カンパニー | レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド |
US7115632B1 (en) * | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
NZ513432A (en) * | 1999-01-13 | 2004-02-27 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
JP2005508322A (ja) * | 2001-09-24 | 2005-03-31 | ジェシー エル エス オウ | 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分 |
EP1534262A1 (fr) * | 2002-07-17 | 2005-06-01 | Titan Pharmaceuticals, Inc. | Combinaison de medicaments chimiotherapeutiques visant a augmenter l'activite antitumorale |
PT1545553E (pt) * | 2002-07-30 | 2011-09-12 | Aeterna Zentaris Gmbh | Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais |
JP2008535924A (ja) * | 2005-04-12 | 2008-09-04 | エラン ファーマ インターナショナル リミテッド | ナノ粒子キナゾリン誘導体製剤 |
KR20070122575A (ko) * | 2005-04-22 | 2007-12-31 | 깃세이 야쿠힌 고교 가부시키가이샤 | 4'-{2-[(1s, 2r)-2-히드록시-2-(4-히드록시페닐)-1-메틸에틸아미노]에톡시}-3-이소프로필-3', 5'-디메틸비페닐-4-카르복실산 염산염의 결정 다형 |
PL1912636T3 (pl) * | 2005-07-21 | 2015-02-27 | Ardea Biosciences Inc | N-(aryloamino)sulfonamidowe inhibitory mek |
JP2007099763A (ja) * | 2005-09-08 | 2007-04-19 | Toyama Chem Co Ltd | ピペラシリンナトリウム・1水和物の新規な結晶及びその製造方法 |
TW200800150A (en) * | 2005-12-21 | 2008-01-01 | Organon Nv | Compounds with medicinal effects due to interaction with the glucocorticoid receptor |
-
2008
- 2008-07-28 CN CN201310317815.8A patent/CN103479604B/zh not_active Expired - Fee Related
- 2008-07-28 WO PCT/US2008/071392 patent/WO2009018233A1/fr active Application Filing
- 2008-07-28 CN CN2008801088296A patent/CN101808516B/zh not_active Expired - Fee Related
- 2008-07-28 NZ NZ582929A patent/NZ582929A/en not_active IP Right Cessation
- 2008-07-28 KR KR1020157020493A patent/KR20150091434A/ko not_active Application Discontinuation
- 2008-07-28 EA EA201000268A patent/EA020624B1/ru not_active IP Right Cessation
- 2008-07-28 KR KR1020107004742A patent/KR20100092424A/ko active Search and Examination
- 2008-07-28 EP EP08796733.7A patent/EP2184984A4/fr not_active Ceased
- 2008-07-28 AP AP2010005134A patent/AP2817A/xx active
- 2008-07-28 EA EA201400552A patent/EA032294B1/ru not_active IP Right Cessation
- 2008-07-28 BR BRPI0815659-0A2A patent/BRPI0815659A2/pt not_active Application Discontinuation
- 2008-07-28 MX MX2010001244A patent/MX2010001244A/es active IP Right Grant
- 2008-07-28 AU AU2008282338A patent/AU2008282338B2/en not_active Ceased
- 2008-07-28 JP JP2010520118A patent/JP2010535232A/ja active Pending
- 2008-07-28 KR KR1020147017261A patent/KR20140098185A/ko not_active Application Discontinuation
- 2008-07-28 CA CA2693390A patent/CA2693390C/fr not_active Expired - Fee Related
-
2010
- 2010-01-13 IL IL203296A patent/IL203296A/en not_active IP Right Cessation
- 2010-01-29 CR CR11244A patent/CR11244A/es not_active Application Discontinuation
- 2010-01-29 TN TNP2010000049A patent/TN2010000049A1/fr unknown
- 2010-01-29 SV SV2010003469A patent/SV2010003469A/es unknown
- 2010-01-29 DO DO2010000045A patent/DOP2010000045A/es unknown
- 2010-01-29 EC EC2010009910A patent/ECSP109910A/es unknown
- 2010-01-29 HN HN2010000203A patent/HN2010000203A/es unknown
- 2010-01-29 CO CO10009526A patent/CO6470808A2/es not_active Application Discontinuation
- 2010-02-19 MA MA32636A patent/MA31881B1/fr unknown
-
2011
- 2011-02-18 HK HK11101625.8A patent/HK1147396A1/xx not_active IP Right Cessation
-
2014
- 2014-11-14 JP JP2014231450A patent/JP6309880B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-28 AU AU2015200390A patent/AU2015200390B2/en not_active Ceased
- 2015-08-28 PH PH12015501914A patent/PH12015501914A1/en unknown
-
2017
- 2017-02-03 JP JP2017018477A patent/JP2017125021A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2693390C (fr) | Derives de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procedes d'utilisation et procedes de preparation de ceux-ci | |
US8648116B2 (en) | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | |
US8808742B2 (en) | Compositions and methods for preparing and using same | |
US8829052B2 (en) | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK | |
US7842836B2 (en) | N-aryl-N'alkyl sulfamides as MEK inhibitors | |
US8252842B2 (en) | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof | |
TWI481590B (zh) | 作為mek抑制劑之n-(芳胺基)磺醯胺(包括多晶型)衍生物及組合物,使用方法及其製備方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20130704 |
|
MKLA | Lapsed |
Effective date: 20190729 |